Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KLRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKailera advances oral obesity drug to Phase 3, completes high-dose injection trial enrollment
Filed August 12, 2026 · Period ending August 12, 2026 · ~1 min read
Key Changes
-
high
IND for oral ribupatide (GLP-1/GIP dual agonist) now active with FDA; global Phase 3 obesity trials planned for first half of 2027, advancing the oral candidate toward pivotal studies.
Exhibit 99.1 view on EDGAR → -
high
Phase 2b high-dose trial of injectable ribupatide fully enrolled with 264 participants testing doses up to 20 mg over 48 weeks; data expected mid-2027 to inform optimal dosing.
Exhibit 99.1 view on EDGAR → -
high
Exhibit 99.1 view on EDGAR →
-
medium
Appointed Nur Nicholson as Chief Technology Officer (technical operations, manufacturing) and Kathleen Tregoning as Chief Corporate Affairs Officer, strengthening operational and external affairs capabilities.
Exhibit 99.1 view on EDGAR → -
medium
Added to Russell 2000 Index effective June 29, 2026, following annual reconstitution; inclusion typically increases institutional ownership and trading liquidity.
Exhibit 99.1 view on EDGAR →
Summary
Kailera reported Q2 2026 results and provided updates on its obesity pipeline, marking two key clinical milestones. The company's IND for oral ribupatide (KAI-9531-T), a GLP-1/GIP dual agonist, is now active with the FDA, clearing the path to initiate global Phase 3 obesity trials in the first half of 2027. Separately, Kailera completed enrollment of 264 participants in its U.S.
Phase 2b high-dose trial of injectable ribupatide, testing doses up to 20 mg over 48 weeks in adults with BMI ≥35 without type 2 diabetes; data expected mid-2027 will inform optimal dosing for the injectable formulation. Financially, Kailera held $1.17 billion in cash and marketable securities as of June 30, 2026, sufficient to fund operations into mid-2028.
Net loss widened to $111.3 million from $28.9 million in Q2 2025, driven by R&D spending that increased to $101.1 million from $19.5 million year-over-year, reflecting expanded clinical programs and manufacturing costs. The company strengthened its leadership team with two C-suite appointments—Nur Nicholson as Chief Technology Officer and Kathleen Tregoning as Chief Corporate Affairs Officer—and was added to the Russell 2000 Index effective June 29, 2026. For retail holders, the Phase 3 readiness of the oral candidate and the mid-2027 high-dose injectable data are the near-term catalysts to watch, with the cash runway providing visibility through both events.
Section-by-Section Diff
Event · Exhibit 99.1
Kailera reports Q2 2026 results, advances obesity pipeline with Phase 3 trials planned for 2027, and expands executive team.
Added in current filing · view on EDGAR →
Appointed Nur Nicholson as Chief Technology Officer: Nur brings nearly three decades of experience leading global technical operations, manufacturing, quality, supply chain and other organizations across the pharmaceutical and biotechnology industries. She previously served as Chief Technical Operations Officer at Apellis Pharmaceuticals, where she built and led the company's technical operations organization through its transition from clinical-stage biotech to commercial-scale enterprise. ... Appointed Kathleen Tregoning as Chief Corporate Affairs Officer: Kathleen brings more than two decades of experience leading global corporate affairs organizations and guiding innovative biopharmaceutical companies through complex policy, regulatory, reputational, and stakeholder environments. She previously served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, where she helped lead the neuroscience company through a period of significant growth prior to its acquisition by AbbVie in 2024.
Kailera appointed Nur Nicholson as Chief Technology Officer to lead technical operations and manufacturing, bringing experience from Apellis Pharmaceuticals. Kathleen Tregoning joined as Chief Corporate Affairs Officer, bringing corporate affairs and commercial strategy experience from Cerevel Therapeutics. These appointments strengthen the company's operational and external affairs capabilities as it advances toward commercialization.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 13, 2026 · How we verify